Physician profile
Robin Strait
NPI 1447615919
$4,957.64
in general payments reported to CMS, 2019-2025
25 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $848 · 2023: $1,479 · 2024: $1,069 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,612 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,611.57 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $778.54 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $740.73 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $634.18 | 2023-2025 | |
| Pfizer INC. | $548.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.09 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $302.99 | 2022-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $197.18 | 2021-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $188.60 | 2022-2023 | Verquvo |
| Axsome Therapeutics, INC. | $149.22 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.67 | 2021 | |
| Boston Scientific Corporation | $121.23 | 2023 | Watchman |
| Inspire Medical Systems, INC. | $104.49 | 2024-2025 | Inspire |
| Amgen INC. | $96.80 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $96.06 | 2024-2025 | |
| Irhythm Technologies, INC. | $86.83 | 2023-2024 | Zio Xt Patch, Zio Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $79.02 | 2025 | Nuzyra |
| Corium, LLC | $63.20 | 2023 | Azstarys |
| Novo Nordisk INC | $39.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $29.67 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $28.46 | 2025 | Amvuttra |
| Abbvie INC. | $24.58 | 2025 | |
| Cashflow Solutions, LLC | $23.56 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Itamar Medical INC | $20.44 | 2024 | Watchpatone |
| Lilly USA, LLC | $18.64 | 2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2025 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Strait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.